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To the Editor: Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous inherited neuropathy, with Type 1A being the most common. CMT 1A is characterized by progressive weakness and atrophy of the distal limb muscles beginning in the peroneal group, mild distal sensory loss, diminished tendon reflexes, and slow nerve conduction velocity. [1] Spinal nerve root hypertrophy is a distinct sign of CMT 1A. [2] This sign can be detected on magnetic resonance images (MRI), but it is often overlooked. Instead, diagnosis of this disease is often made basing on biopsy and genetic testing.
A 28-year-old woman was admitted to our neurology unit with a 2-year history of progressive lower extremity weakness accompanied with muscle atrophy. Two years before admission, she first experienced decreased strength in both lower limbs that was more severe on the right with mild foot drop. These symptoms progressed until the patient noticed decreased muscle mass of both lower extremities. Her father and elder sister had similar manifestations. Neurological examinations revealed level IV distal muscular strength in both upper extremities and left lower extremity, and level III muscular strength in her right lower extremity, with hyporeflexia of the bilateral tendon reflex. Bilateral calf (especially gastrocnemius), thenar, hypothenar, and first dorsal interosseous muscles showed atrophy. In addition, pes cavus was observed, and pain sensation of the distal lower limbs was mildly decreased. Cerebral spinal fluid (CSF) examination showed normal white blood cell count (1 × 10 6 /L) and protein level (360 mg/L, normal range: 150-450 mg/L). A nerve conduction study (NCS) showed uniformly reduced velocity and delayed latency in all four extremities. Compound muscle activation potential and sensory nerve action potential were grossly reduced, especially in the lower extremities. F wave was absent in the right tibial nerve. Needle electromyography showed motor unit potentials with prolonged duration and increased amplitude, indicating chronic denervation.
MRI of the spine revealed markedly hypertrophic cauda equina and nerve roots that almost completely filled the spinal canal in the cervical (C5-C7) and lumbosacral areas (L3-S3), and the thecal sac was mildly enhanced with gadolinium-diethylenetriamine pentaacetic acid in these areas [ Figure 1 ]. Sural nerve biopsy revealed nerve demyelination, axonal degeneration, and an obvious loss of large myelinated fibers, accompanied by Schwann cell proliferation and onion bulb formation. Duplication of the peripheral myelin protein 22 gene was confirmed by a genetic sequence test. Therefore, the diagnosis of CMT 1A was established.
Enlargement of nerve roots, which is a distinct feature of hypertrophic neuropathy, has been frequently reported in neurofibromatosis and chronic inflammatory demyelinating polyneuropathy (CIDP). [3, 4] This phenomenon can also be seen in CMT disease that caused by onion-bulb formation, but rare been reported. Our case had been misdiagnosed with neurofibromatosis twice and with CIDP once at different local hospitals. Despite the many similarities between CMT 1A and neurofibromatosis, there are some major differences. First, in contrast to the smooth enlargement of nerve roots seen in CMT 1A, neurofibromatosis is characterized by nodular enlargement. Second, patients of neurofibromatosis often have typical skin manifestations of cafe au lait spots or Lisch nodules. Third, the lack of neural foramina erosion or widening on MRI helped us rule out the diagnosis of neurofibromatosis.
Nerve root hypertrophy is also present in CIDP. It is difficult to distinguish CMT 1A from CIDP basing on findings on MRI In contrast, nonuniform abnormalities in nerve conduction tend to present in CIDP. In addition, protein-cell separation in CSF is supportive for the diagnosis of CIDP, but not usually seen in CMT 1A.
The above-mentioned features do no progress consistently at different stages of these diseases, therefore, the differential diagnosis should remain broad and be based on clinical characteristics such as a family history, physical findings, CSF laboratories, appropriate imaging, and electrophysiological and pathological features. If necessary, genetic tests are needed. 
